Heart failure & cardiomyopathies
Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis
Authors' conclusion
ATTR-CM is associated with diagnostic delays from initial suspicion to therapy initiation. While diagnostic and treatment timelines have improved, enhanced awareness, supraregional networks, specialized centres and focused education are essential to improve diagnosis and outcomes. Increasing awareness has led to patients being diagnosed at earlier disease stages, underscoring the potential to positively impact patient prognosis.
Study context
- Population
- Patients with ATTR-CM receiving transthyretin stabilizer therapy at the West German Amyloidosis Center (01/2018–12/2023)included in the analysis after screening 254 patients
- Participants
- 154 patients
- Comparison
- Diagnostic timelines were compared across two periods.
- Outcome
- Time to diagnosis
Main finding
As reported in the abstract
P < 0.001
Further findings
Duration from diagnosis to stabilizer therapy · reduced in the second period
P < 0.001
- Duration from diagnosis to stabilizer therapy — Overall median duration
- 84 (44-160) days
- LVEF · lower LVEF in the first period
- P < 0.001
- NAC stages · more advanced NAC stages in the first period
- P = 0.004
- Women diagnosed · more women diagnosed in the second period
- P = 0.010
Baseline characteristics
- ATTRwt
- 96.8%
- Median age
- 80 (76-83) years
- Male
- 87%
- NYHA class ≥III
- 46.6%
Original publication
Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis. ESC Heart Fail. Published 28 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →